MMI - Medical Microinstruments, Inc. Symani® surgical system named a TIME Best Invention of 2024 #surgicalrobotics #microsurgery https://lnkd.in/gDA7hNWy
Fountain Healthcare Partners
Venture Capital and Private Equity Principals
Dublin, Dublin 1,486 followers
About us
Fountain Healthcare Partners is a life science venture capital firm based in Dublin Ireland with an office in New York. Fountain currently manages over €300M and is actively investing its third fund raised in 2019. The team at Fountain originally worked within the corporate VC group at Elan Corporation and raised its first independent fund in 2008. Fountain invests in drugs, devices and diagnostics with a focus on companies developing innovative products that address unmet medical needs and deliver significant pharmacoeconomic benefits.
- Website
-
http://www.fh-partners.com
External link for Fountain Healthcare Partners
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Dublin, Dublin
- Type
- Partnership
- Founded
- 2008
- Specialties
- Venture Capital, Life Sciences, Medical Devices, Drug Delivery, Pharmaceuticals, Diagnostics, Speciality Pharma, and Biotechnology
Locations
-
Primary
Get directions
Two Docklands Central, Level 4
Guild St
Dublin, Dublin D01 K2C5, IE
-
Get directions
205 East 42nd St., 20th Floor
New York, NY 10017, US
Employees at Fountain Healthcare Partners
Updates
-
Vivasure Medical Ltd. announces positive results of PATCH IDE pivotal study indicating safety and efficacy of Perqseal large hole closure device. https://lnkd.in/e8rvfUnm
-
Mainstay Medical announces that the US Centers for Disease Control and Prevention has designated a new ICD 10 diagnosis code for multifidus dysfunction. #chroniclowerbackpain #neuromodulation https://lnkd.in/e5XJrpa8
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction — Fountain Healthcare Partners
fh-partners.com
-
Neurent Medical announces the publication of positive six-month results from the PARAGON clinical study in Ear, Nose & Throat Journal. The study demonstrates that treatment with Neurent Medical's NEUROMARK® System, a radiofrequency ablation device indicated for chronic rhinitis, led to significant improvements in #rhinitis symptoms, ear symptoms, and quality of life. https://lnkd.in/eSVbFCzj
-
Fountain Healthcare Partners reposted this
Founding CEO of Neuromod, inventors of LENIRE, the world’s first and only FDA approved bimodal neuromodulation device for tinnitus.
Fantastic talk by Dr. Tish Ramirez AuD and Dr. Emily E. McMahan, AuD at #AuDACITY2024 on the highly consistent clinical trial and real-world #Lenire data. Intriguing comparison of outcomes of #Lenire patients with #HearingAids versus those who don’t. Conclusion: hearing aids seem to have no additional impact on #Tinnitus outcomes for patients treated with #Lenire #audpeeps #audiology #audiologist #tinnitus #hearingloss #hearingaids #hearingcare #hearinghealth #hearinghealthcare For more on #Lenire, the #FirstAndOnly FDA-approved #bimodal #tinnitus #treatment, see: https://www.lenire.com/
-
-
-
-
-
+7
-
-
Fountain Healthcare Partners reposted this
September is #WorldSinusHealthAwarenessMonth and at Neurent Medical, we are proud to recognize and celebrate all of the dedicated ENTs and referring physicians who work hard every day to help patients overcome the annoyance, frustration, and embarrassment of Chronic Rhinitis (CR) symptoms. Visit neurentmedical.com to learn more about NEUROMARK for patients with CR and how it may help your patients find relief by treating the source of their symptoms.* *Please see Instructions for Use (IFU) for a complete listing of warnings, precautions, and adverse events. #NEUROMARK #PNN #PNNAblation #ENT #Otolaryngology #BreatheHappy #DitchTheTissues
-
Neuromod Devices announces publication of pivotal FDA controlled clinical trial (TENT-A3) data in Nature Communications. #tinnitus #neuromodulation https://lnkd.in/ee7UCtdn
Founding CEO of Neuromod, inventors of LENIRE, the world’s first and only FDA approved bimodal neuromodulation device for tinnitus.
Delighted to announce the publication of our pivotal FDA controlled clinical trial data in Nature Communications, a top-tier peer-reviewed journal in the Nature Portfolio. Building on the findings of the TENT-A1 and TENT-A2 clinical trials (also published in top-tier Science Magazine and Nature Portfolio peer-reviewed journals), the TENT-A3 trial data combined with Real-World Evidence was the basis for our landmark FDA De Novo approval of #Lenire, the #FirstAndOnly FDA-approved #bimodal #neuromodulation #tinnitus #treatment device. Nature Communications Paper: https://lnkd.in/ek32pz7W Press Release: https://lnkd.in/eR8Aephd #audpeeps #audiology #tinnituscare #TinnitusExperts #hearing #hearinghealth #hearinghealthcare #hearingloss #ENT #otolaryngology #peerreviewed #clinicaltrials
-
-
Hear our very own Cecilia Caetano share some valuable tips on how women* can take steps to improve the management of their menopause. Let's break the stigma and encourage every woman* to take charge of their menopause experience. Click here to learn more: 👇👇 #MenoScienceNotSilence #TeamBayer
-
Medical Microinstruments, Inc. Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System First-of-its-kind procedure a breakthrough in expanding robotic capability to complex neurosurgical care https://lnkd.in/evEkq23d
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
businesswire.com